Tesamorelin: The FDA-Approved Peptide for Visceral Fat

TL;DR: Tesamorelin is a synthetic 44-amino acid growth hormone-releasing hormone (GHRH) analog and the only FDA-approved medication specifically for reducing visceral abdominal fat. Sold under the brand name Egrifta, it stimulates the pituitary gland to produce growth hormone naturally — preserving the body's pulsatile GH release pattern unlike direct HGH injection. In Phase III clinical trials (Falutz et al., 2010), tesamorelin reduced visceral fat by approximately 15-18% over 26 weeks, with 69% of patients achieving clinically significant reduction. It is commonly stacked with ipamorelin for enhanced GH release and body composition results.

What Is Tesamorelin?

Tesamorelin is a synthetic peptide consisting of all 44 amino acids of human GHRH with an added trans-3-hexenoic acid group for stability. Developed by Theratechnologies, it received FDA approval in 2010 under the brand name Egrifta for reducing excess visceral abdominal fat in HIV-associated lipodystrophy. A newer formulation, Egrifta WR (F8), was approved in March 2025 with improved reconstitution convenience.

It is classified as a secretagogue — rather than injecting growth hormone directly, tesamorelin stimulates your pituitary gland to produce and release its own endogenous GH. This preserves the body's natural pulsatile release pattern and negative feedback loops, which is a critical distinction from exogenous HGH therapy.

Tesamorelin remains the only FDA-approved medication specifically indicated for visceral adipose tissue reduction. While approved for HIV-associated lipodystrophy, it is widely used off-label in anti-aging, wellness, and body composition protocols for its targeted visceral fat reduction effects.

How Tesamorelin Works

Tesamorelin binds to GHRH receptors on the anterior pituitary gland, triggering the natural cascade of growth hormone synthesis and secretion. The growth hormone then travels to the liver and tissues, stimulating IGF-1 production, which mediates the downstream effects on body composition and metabolism.

Why It Targets Belly Fat

Tesamorelin's primary clinical effect — visceral fat reduction — occurs through GH-mediated lipolysis. Growth hormone activates hormone-sensitive lipase in fat cells, promoting breakdown of stored triglycerides into free fatty acids. Visceral fat cells are especially responsive because they have a higher density of beta-adrenergic receptors and are more metabolically active than subcutaneous fat cells. This is why tesamorelin preferentially reduces deep abdominal fat rather than surface-level fat.

Pulsatile GH Release

A critical advantage over direct HGH injection: tesamorelin maintains pulsatile GH secretion — the body's natural pattern of releasing growth hormone in bursts, with the largest pulse during deep sleep. This pulsatile pattern prevents GH receptor desensitization and keeps the body's somatostatin feedback loop intact, reducing the risk of supraphysiological GH levels and their associated side effects.

Tesamorelin vs HGH

This is the most common comparison question — and the differences matter significantly.

Bottom line: Tesamorelin is preferred when the goal is targeted visceral fat reduction with a more physiologic GH pattern. HGH is used for documented GH deficiency or broader anabolic goals under tight medical supervision.

The Tesamorelin + Ipamorelin Stack

One of the most popular peptide stacks combines tesamorelin with ipamorelin — and there's a clear mechanistic rationale for why.

How the Stack Works

• Tesamorelin (GHRH analog) binds to GHRH receptors on the pituitary, signaling it to produce and release growth hormone
• Ipamorelin (GHRP/ghrelin mimetic) binds to ghrelin receptors on the pituitary and suppresses somatostatin — the hormone that normally puts the brakes on GH release

Together, tesamorelin pushes the gas while ipamorelin releases the brake. The result is a synergistic GH pulse significantly greater than either peptide alone.

Why This Stack Is Popular

• Enhanced visceral fat reduction compared to tesamorelin alone
• Better body composition — more fat loss with preserved or improved lean mass
• Improved sleep and recovery — ipamorelin's GH pulses during sleep enhance deep sleep quality
• Clean side effect profile — ipamorelin is selective for GH release without spiking cortisol or prolactin levels (unlike older GHRPs like GHRP-6)

Stack Protocol

Common clinical protocols for the tesamorelin/ipamorelin combination:

• Tesamorelin: 1-2mg subcutaneously at bedtime
• Ipamorelin: 100-300mcg subcutaneously at bedtime (same injection window)
• Cycle: 8-12 weeks on, 4 weeks off
• Monitoring: IGF-1, fasting glucose, lipids at baseline and mid-cycle

Many suppliers offer pre-blended tesamorelin/ipamorelin formulations for convenience.

Quality sourcing matters for peptide stacks. Look for suppliers providing third-party HPLC and mass spectrometry testing on every batch. We recommend Fountain of Youth — they carry a tesamorelin/ipamorelin blend (10mg/3mg) with certificates of analysis and proper cold-chain shipping.

Benefits

Based on clinical trial data and published research:

• Visceral fat reduction. 15-18% reduction in deep abdominal fat over 26 weeks in Phase III trials. About 69% of treated patients achieved clinically significant reduction vs 33% on placebo. Specifically targets the visceral fat most associated with cardiovascular and metabolic risk.
• Body composition improvement. Increased lean body mass with reduced waist circumference (approximately 2-3cm over 26 weeks). Total scale weight may not change much — fat loss is offset by lean tissue gains.
• Liver fat reduction. Tesamorelin has shown significant reductions in hepatic fat content, with improved liver enzymes in patients with abdominal obesity. This is relevant for fatty liver disease (MASH/NAFLD).
• Lipid profile. Clinical trials demonstrated reduced triglycerides and improved fat distribution ratios. These lipid improvements contribute to reduced cardiovascular risk.
• Cognitive function. A study by Friedman et al. (2013) found tesamorelin improved executive function and verbal memory in older adults with mild cognitive impairment over 20 weeks — effects mediated by GH and IGF-1's neurotrophic properties.
• Sleep quality. The largest natural GH pulse occurs during deep sleep. Tesamorelin amplifies this pulse, and users consistently report improved sleep quality as one of the first noticeable effects.

Dosing

FDA-Approved Dose

• Original (Egrifta SV): 2mg injected subcutaneously once daily
• Updated (Egrifta WR, approved March 2025): 1.28mg with improved formulation and weekly reconstitution convenience
• Injection site: Abdomen, rotating sites, avoiding the navel area
• Timing: Same time each day, on an empty stomach or at bedtime (at least 2-3 hours after last meal)

Off-Label Protocol for Visceral Fat

• Dose: 1-2mg subcutaneously once daily
• Timing: Bedtime preferred — mimics the natural nighttime GH surge and avoids the GH-blunting effect of food
• Cycle length: 8-12 weeks, with reassessment via DEXA scan, CT, or waist/waist-to-hip measurements
• Breaks: 4-week break between cycles, or continuous use with regular monitoring
• Monitoring: IGF-1 levels (ensure they stay within normal range), fasting glucose, lipid panel

Key Principles

• Empty stomach is critical — carbohydrates and fats blunt the GH response
• Consistency matters — inject at roughly the same time each day
• Results require patience — visceral fat reduction becomes measurable around weeks 8-12, with maximum effect by week 26
• Discontinuation = rebound — clinical data shows visceral fat returns to baseline after stopping treatment

Timeline: What to Expect

Weeks 1-4: GH and IGF-1 levels begin rising. Improved sleep quality and recovery are typically the first effects noticed. Some report increased energy and enhanced workout recovery.

Weeks 4-8: Body composition changes become noticeable. Reduced waist circumference, improved skin quality. Tesamorelin + ipamorelin stack users often report significant fat reduction beginning in this window.

Weeks 8-16: Significant measurable visceral fat reduction. Improvements in lean body mass. Bloodwork may show improved fasting glucose and lipid profiles.

Weeks 16-26: Full clinical effects as demonstrated in trials. Maximum visceral fat reduction typically achieved by week 26 with continued maintenance.

Beyond 26 weeks: Benefits maintained with continued use. In the LIPO-011 trial, patients on continuous tesamorelin maintained their fat reduction through 52 weeks.

Side Effects & Safety

Common Side Effects

• Injection site reactions — redness, swelling, itching at injection site (most frequent side effect)
• Arthralgia — joint pain, typically mild
• Peripheral edema — fluid retention in hands and feet
• Myalgia — muscle pain

Less Common

• Paresthesia — numbness or tingling
• Carpal tunnel-like symptoms — related to fluid retention
• Increased blood glucose — monitor closely if diabetic or prediabetic
• Nausea — typically transient

Important Safety Considerations

• Contraindicated with active malignancy — GH can promote tumor growth
• Blood glucose monitoring required — tesamorelin can increase glucose levels
• IGF-1 monitoring — check periodically to ensure levels stay in normal range
• Pituitary conditions — patients with pituitary surgery/irradiation may have reduced response
• Pregnancy — should not be used during pregnancy

Growth Hormone Peptides Compared (2026)

Goal-based selection: For visceral fat, tesamorelin is the clear leader. For anti-aging and recovery with minimal side effects, ipamorelin + CJC-1295 is the most popular stack. For maximum GH output, the tesamorelin + ipamorelin combination targets both pathways simultaneously.

Where to Buy Tesamorelin

Tesamorelin is FDA-approved (Egrifta/Egrifta WR) and available by prescription for HIV-associated lipodystrophy. For research and off-label use, it is available from peptide suppliers — often in combination with ipamorelin.

When sourcing, look for:

• Third-party HPLC and mass spectrometry testing
• Published certificates of analysis for every batch
• Proper cold-chain shipping

We recommend Fountain of Youth for their tesamorelin/ipamorelin blend (10mg/3mg) with full COA documentation and third-party testing.

Frequently Asked Questions

What is tesamorelin? Tesamorelin is a synthetic 44-amino acid growth hormone-releasing hormone (GHRH) analog. It is FDA-approved under the brand name Egrifta for reducing excess visceral abdominal fat. Unlike direct HGH injections, tesamorelin stimulates your pituitary gland to produce its own growth hormone naturally, preserving the body's pulsatile release pattern and feedback loops.

Does tesamorelin reduce belly fat? Yes. In Phase III clinical trials, tesamorelin reduced visceral adipose tissue (deep belly fat around organs) by approximately 15-18% over 26 weeks. About 69% of treated patients achieved clinically significant fat reduction vs 33% on placebo. It specifically targets visceral fat — not subcutaneous fat — through GH-mediated lipolysis.

Tesamorelin vs HGH — what's the difference? Tesamorelin is a secretagogue that stimulates your body to produce its own growth hormone in natural pulses. HGH is direct injection of synthetic growth hormone that bypasses pituitary regulation. Tesamorelin preserves feedback loops, has lower risk of insulin resistance and side effects, is FDA-approved for fat reduction, and is significantly cheaper than HGH therapy.

Can you stack tesamorelin with ipamorelin? Yes — this is one of the most popular peptide stacks. Tesamorelin (GHRH analog) stimulates GH release while ipamorelin (GHRP/ghrelin mimetic) suppresses somatostatin and amplifies the signal through a different receptor pathway. Together they produce a synergistic GH pulse greater than either alone, enhancing visceral fat reduction, body composition, sleep, and recovery.

What is the tesamorelin dosage for visceral fat? The FDA-approved dose is 2mg injected subcutaneously once daily (or 1.28mg with the newer Egrifta WR formulation). Inject in the abdomen with rotating sites, typically at bedtime to mimic natural nighttime GH release. Off-label protocols often run 8-12 week cycles. IGF-1 and blood glucose should be monitored.

What are the side effects of tesamorelin? Common side effects include injection site reactions, joint pain (arthralgia), peripheral edema (fluid retention), and muscle pain. Less common effects include increased blood glucose, carpal tunnel-like symptoms, and paresthesia. Tesamorelin is contraindicated in patients with active malignancy. Side effects are generally mild and dose-dependent.

What is the best peptide for growth hormone release? It depends on your goal. For visceral fat reduction: tesamorelin is the most potent and only FDA-approved option. For anti-aging, sleep, and recovery: ipamorelin or an ipamorelin + CJC-1295 stack offers clean GH pulses without cortisol/prolactin spikes. For maximum effect: the tesamorelin + ipamorelin stack combines both pathways for synergistic GH release.

Will belly fat come back if I stop tesamorelin? Yes. In the LIPO-011 clinical trial, patients who switched from tesamorelin to placebo at week 26 saw visceral fat return to baseline levels. This means ongoing treatment is needed to maintain fat reduction. Most practitioners recommend 3-6 month cycles with reassessment via DEXA scan or waist measurements.

Sources

1. Falutz, J., Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359-2370. DOI: 10.1056/NEJMoa072375

2. Falutz, J., Potvin, D., Mamputu, J.C., et al. (2010). Effects of tesamorelin in human immunodeficiency virus-infected patients with excess abdominal fat: pooled analysis of Phase 3 trials. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291-4304. DOI: 10.1210/jc.2010-0490

3. Stanley, T.L., Feldpausch, M.N., Oh, J., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients. JAMA, 312(4), 380-389. DOI: 10.1001/jama.2014.8334

4. Friedman, S.D., Baker, L.D., Borber, S., et al. (2013). Growth hormone-releasing hormone effects on brain GABA levels in mild cognitive impairment. JAMA Neurology, 70(7), 883-890. DOI: 10.1001/jamaneurol.2013.1425

5. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. PMC. PMC liver enzymes study

6. Theratechnologies Inc. (2025). Egrifta WR (tesamorelin F8) Prescribing Information. FDA

7. Tesamorelin - LiverTox. NCBI Bookshelf. LiverTox